文献速递肾癌与肾肿瘤

新辅助阿昔替尼降期cT2a肾肿瘤以行部分肾切除术的II期研究

Evaluation of axitinib to downstage cT2a renal tumours and allow partial nephrectomy: a phase II study.
PubMed 文献 · BJU Int · 2018-11-20

这项前瞻性多中心II期AXIPAN试验评估新辅助阿昔替尼能否将cT2a clear-cell RCC从根治性肾切除术转为部分肾切除术适应证。16例肿瘤直径缩小,中位缩小17%(64.0 vs 76.5 mm,P < 0.001),12例因肿瘤<7 cm而达到主要终点并接受PN。结论认为新辅助阿昔替尼可行,但PN仍复杂并可能伴随并发症。

要点

  • cT2a clear-cell RCC不适合PN者,新辅助阿昔替尼可使肿瘤中位缩小17%。
  • PN手术仍复杂,需手术专长,并可能伴随并发症。

核心结论

  • 新辅助阿昔替尼在cT2 clear-cell RCC中可行,即使肿瘤缩小幅度不大,仍使12例肿瘤缩小至<7 cm。
  • PN手术仍然复杂,需要手术专长,并可能伴随并发症。

研究设计与样本

  • 前瞻性、多中心、II期试验(AXIPAN)。
  • 阿昔替尼5 mg,可增至7-10 mg,每日两次,术前2-6个月,依据影像学反应决定。

主要发现

  • 中位(范围)肿瘤大小和RENAL肾测量评分分别为76.5(70-98)mm和11(7-11)。
  • 阿昔替尼新辅助治疗后,16例肿瘤直径缩小,中位缩小17%(64.0 vs 76.5 mm;P < 0.001)。
  • 12例因肿瘤<7 cm接受PN,达到主要终点;16例接受了PN。
  • 5例发生3级不良事件;5例发生Clavien III-V术后并发症。
  • 2年随访时,6例出现转移进展,2例复发。

关键数值与推荐

  • 主要终点为接受新辅助阿昔替尼后肿瘤<7 cm并接受PN的患者数。
  • 阿昔替尼剂量为5 mg,可增至7-10 mg,每日两次,术前2-6个月。

临床怎么用

  • 对于cT2a clear-cell RCC且不适合PN的患者,新辅助阿昔替尼可作为降期以尝试PN的策略。
  • 即使肿瘤缩小至<7 cm,PN仍可能复杂,需由具备手术专长的术者实施并警惕并发症。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate the ability of neoadjuvant axitinib to reduce the size of T2 renal cell carcinoma (RCC) for shifting from a radical nephrectomy (RN) to a partial nephrectomy (PN) indication, offering preservation of renal function. PATIENTS AND METHODS: Patients with cT2aN0NxM0 clear-cell RCC, considered not suitable for PN, were enrolled in a prospective, multicentre, phase II trial (AXIPAN). Axitinib 5 mg, and up to 7-10 mg, was administered twice daily, for 2-6 months before surgery, depending on the radiological response. The primary outcome was the number of patients receiving PN for a tumour <7 cm in size after neoadjuvant axitinib. RESULTS: Eighteen patients were enrolled. The median (range) tumour size and RENAL nephrometry score were 76.5 (70-98) mm and 11 (7-11), respectively. After axitinib neoadjuvant treatment, 16 tumours decreased in diameter, with a median size reduction of 17% (64.0 vs 76.5 mm; P < 0.001). The primary outcome was considered achieved in 12 patients who underwent PN for tumours <7 cm. Sixteen patients underwent PN. Axitinib was tolerated in the present study, as has been previously shown in the metastatic setting. Five patients had grade 3 adverse events. Five patients experienced Clavien III-V post-surgery complications. At 2-year follow-up, six patients had metastatic progression, and two had a recurrence. CONCLUSION: Neoadjuvant axitinib in cT2 ccRCC is feasible and, even with a modest decrease in size, allowed a tumour shrinkage <7 cm in 12 cases; however, PN procedures remained complex, requiring surgical expertise with possible morbidity.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Lebacle C, Bensalah K, Bernhard JC, et al. Evaluation of axitinib to downstage cT2a renal tumours and allow partial nephrectomy: a phase II study. BJU Int. 2018. PMID: 30288884. doi:10.1111/bju.14581

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。